Document Detail


Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. Cefpirome Study Group.
MedLine Citation:
PMID:  1601764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Two hundred and seventy-six hospitalized patients with severe infection (complicated UTI, pneumonia, skin and soft tissue infection or septicaemia) were randomly allocated to receive either 1g or 2g cefpirome bd. Two hundred and seventy-four patients were evaluable for tolerance, 210 for bacteriological efficacy. The two groups were similar in terms of underlying disease, age, sex, and general condition on admission. The overall clinical and bacteriological response rates were 97/103 (94%) and 68/76 (90%) respectively in the 1g group, compared with 102/107 (95%) and 67/71 (94%) in the 2g group. There was no significant difference between the treatment groups. Eighteen adverse events, possibly or probably drug related, were reported (7 in the 1g group, 11 in the 2g group). This resulted in discontinuation of therapy in four cases (two in each group). Fourteen of the adverse events were local (five receiving 1g, nine receiving 2g), mainly phlebitis or pain at the injection site. Thirteen patients died during the study period (up to 14 days after the last dose) but in no case was death attributed to cefpirome. A review of routine laboratory parameters revealed no abnormalities which could definitely be attributed to cefpirome although in four cases a relationship was considered possible; these included two increases in serum creatinine, one increase in SGPT, and one episode of neutropenia. Cefpirome administered as 1 or 2g twice daily was a well tolerated, effective agent for the treatment of severe sepsis in hospitalized patients.
Authors:
C Carbon
Related Documents :
24379884 - Effect of low power laser on incisional wound healing.
2074244 - An open multicentre study of the efficacy and tolerance of cefodizime 1 g bd intravenou...
23788234 - Disclosing total waiting times for joint replacement: evidence from the english nhs usi...
24986744 - A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds...
15102154 - Intrathecal clonidine in the treatment of intractable pain: a phase i/ii study.
7832384 - The ramifications of immediate reconstruction in the management of breast cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  29 Suppl A     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  1992 Apr 
Date Detail:
Created Date:  1992-07-14     Completed Date:  1992-07-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  87-94     Citation Subset:  IM    
Affiliation:
Hôpital Bichat, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Bacterial Infections / drug therapy*
Cephalosporins / adverse effects,  therapeutic use*
Cross Infection / drug therapy*
Dose-Response Relationship, Drug
Drug Evaluation
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Prospective Studies
Chemical
Reg. No./Substance:
0/Cephalosporins; 84957-29-9/cefpirome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of cefpirome on pharyngeal and faecal flora after single and multiple intravenous administ...
Next Document:  Cefpirome versus ceftazidime in the treatment of urinary tract infections.